We compared the frequency and sequence of breast imaging and biopsy use for the diagnostic and preoperative workup of breast cancer according to breast magnetic resonance imaging (MRI) use among older women.
BACKGROUND
Diagnosis and preoperative workup for women with breast cancer can include evaluation using several imaging modalities and breast biopsy. Breast magnetic resonance imaging (MRI) is increasingly used as an adjunct imaging modality to determine extent of disease and for preoperative planning. [1] [2] [3] [4] [5] The potential benefits of preoperative MRIsuch as lower reoperation rates, lower likelihood of recurrence, and improved mortality-have not been substantiated in the literature. 6, 7 Higher breast biopsy rates have been associated with preoperative MRI use 8, 9 and greater overall utilization of breast-related services has been hypothesized in relation to breast MRI for women newly diagnosed with breast cancer. 10 With approximately 25% of older women and 58% of younger women with breast cancer receiving a preoperative MRI, 11, 12 it is important to fill gaps in the evidence-base for limitations and benefits of preoperative MRI.
Breast MRI has greater sensitivity than mammography and ultrasound (US) 13, 14 ; thus, detects additional lesions, both cancerous and noncancerous. 9, 15, 16 Detection of additional lesions may lead to further workup before surgical treatment. Increased use of breast services results in additional costs, procedures, and potentially, a delay in treatment. There have been no reports in the literature on differences in number or type of imaging and biopsies used with preoperative and perioperative breast MRI for women with breast cancer. 12 Several studies, however, have shown that use of preoperative breast MRI is significantly associated with 1-3 week delays in treatment. 13, 17 Although a delay in treatment may not impact survival, it can result in psychological burden for women. 13, 18, 19 Comparing mammography, US, and biopsy use during the diagnostic and preoperative workup in relation to preoperative MRI use for women with breast cancer will help elucidate whether there are additional burdens of care that should be considered in weighing the tradeoffs of MRI use.
We examined population-based patterns of breast care for older women with breast cancer who did and did not receive breast MRI in the diagnostic and preoperative periods. Using SEER-Medicare data, we estimated: (1) frequency of breast imaging and breast biopsy by receipt of advanced imaging; (2) imaging and biopsy use sequencing; and (3) time from the first breast imaging use to surgical treatment.
MATERIALS AND METHODS

Data and Study Population
SEER-Medicare data (2004-2010) were used for this study. 20, 21 The study cohort included women aged 66 years or older at the time of an incident breast cancer diagnosis in 2005-2009 with no prior breast cancer (N = 71,193) and concurrent enrollment in Medicare parts A and B. Women were excluded if: they lacked a pathologic breast cancer diagnosis (ie, without a histologic confirmation), were diagnosed in a nursing home, did not receive cancer-directed surgery, did not have at least 1 breast imaging claim (mammogram, US, or MRI) performed during the diagnostic/preoperative window (defined below; 2332 women had surgery on or within days of diagnosis). Lastly, we excluded women who did not receive surgery, as a first course of treatment within 6 months of the diagnosis date (N = 7496), resulting in a final cohort of 53,653 women. The study was approved by the Committee for Protection of Human Subjects.
Main Variable Definitions
The diagnostic/preoperative window was defined as the period between the initial breast imaging or biopsy within 60 days before diagnosis and the primary surgical treatment. We refer to any breast imaging (both screening and diagnostic) or breast biopsy [including the biopsy associated with the initial cancer diagnosis (DXBX)], occurring during the diagnostic/preoperative window as a breast event. We assumed that multiple images occurring on the same day occurred in the following order: (1) mammogram; (2) US; and (3) MRI (ie, MAM|US, MAM|MRI, US|MRI, or MA-M|US|MRI). If a biopsy was performed on the same day as imaging, we considered the imaging to occur first. For each woman, an imaging hierarchy was applied to describe the most advanced imaging modality in the diagnostic/preoperative window as follows: (1) MRI; (2) mammogram and US; and (3) mammogram alone. We classified women as receiving MRI if receipt of MRI occurred anytime during the diagnostic/preoperative window.
Patient and Tumor Characteristics
Women's characteristics included (a) age at diagnosis; (b) race, collapsed to white, black, and other due to small cell sizes; (c) rural or urban residence; (d) SEER registry; (e) ZIP-level median household income; (f) diagnosis year; (g) breast cancer characteristics including: stage, histology, grade, nodal status, hormone receptor status, and size. We categorized primary treatment into mastectomy, breast conserving surgery with radiation or breast conserving surgery without radiation. We measured comorbidities as defined by the Klabunde adaptation of the Charlson index. 22 
Analysis
Frequency distributions of patient and tumor characteristics by the most advanced imaging modality used are presented. Unadjusted per capita breast event rates for the total number of breast events per woman, the number of each imaging breast event type per woman, and the number of biopsy breast events per woman were examined by most advanced imaging modality used. For each group, the mean predicted per capita breast event rates and 95% confidence intervals were estimated using a Poisson model with standardization by predicted margins to adjust for all available patient and tumor characteristics.
Each woman's breast event sequence was chronologically ordered, noting her diagnostic biopsy. To compare the utilization of diagnostic and preoperative workup with and without MRI, women were grouped by number of breast events and we examined the 5 most common breast event sequences.
The women were classified into 2 imaging groups, with and without MRI. After identifying the first occurrence of an MRI or mammogram/US in each imaging group, we analyzed the sequence of breast events after the first imaging event. We dichotomized women according to whether a biopsy occurred after the first imaging event. We report the proportion of women with a subsequent biopsy following an image by image group. Analyses were conducted in SAS 23 and Stata/SE 12.1. 24 
RESULTS
Of the 53,653 women, 10,766 (20%) had an MRI, the majority had mammogram and US (32,178; 60%), and 10,669 (20%) had mammography alone ( On average, women in the MRI group had 5.8 breast events, whereas mammogram and US group had 4.1 and mammography alone, 2.8. The MRI group had a small increase in biopsies compared with the US and mammography alone groups (1.4 vs. 1.2 and 1.2, respectively), but most of the additional breast events were imaging events ( Table 2) . Adjusting the per capita breast event rate for woman and tumor characteristics, we found similar patterns to the unadjusted estimates (Table 3 ). The per capita breast event rate for the mammogram and US group was slightly greater than the mammography alone group, which appears to account for the US exam itself. There were 4254 different breast event sequences among the women in the study cohort (2692 among MRI users, 1562 without MRI). Figure 1 depicts the 5 most common sequences by number of breast events for women with MRI (N = 10,766) and without MRI (N = 42,887). Each sequence is displayed by combination of events on different claim dates and events occurring on the same day (Fig. 1) . Sixty-five percent of women (N = 27,905) with no MRI had 3 (34%) or 4 (31%) breast events with the most common sequence being a mammogram/US on the same day followed by a diagnostic biopsy (N = 6897; 3 breast events). Among women in the MRI group, an MRI occurred postdiagnosis for 9196 women (85%) with 7146 (66%) having 4 (20%), 5 (26%), or 6 (20%) breast events. The most common breast event sequence was a mammogram/US on the same day, followed by a diagnostic biopsy and concluding with an MRI (N = 714; 4 breast events). Among the subgroup of women who had any breast imaging postdiagnosis, a biopsy followed the imaging event for 51% of women without an MRI compared with 26% of women with an MRI (P < 0.001).
DISCUSSION
Evidence of increasing overall imaging rates in the era of advanced imaging [11] [12] [13] 25 has led to concerns about the extent of imaging utilization in many clinical settings, including breast cancer diagnosis and workup. 26 Breslin et al 12 reported a higher number of traditional and advanced imaging tests among women with preoperative MRI, which increased over time (2005) (2006) (2007) (2008) . In their large study population (N = 52,202) of commercially insured younger women (< 65 y), they concluded that advanced imaging was additive rather than replacing traditional imaging in the diagnostic workup of breast cancer. Our study presents similar findings for the Medicare population noting up to 2.5 times compared with mammography alone and 1.5 times for mammography/US among women with breast MRI.
In a prospective multi-institutional study of 969 women with preoperative MRI, Lehman et al 15 reported that 13% underwent biopsy based on the MRI, whereas another study (N = 141) found that 29% of preoperative evaluations led to biopsy. 27 In the present study, we found a modestly higher rate of biopsy among women with and without MRI in the diagnostic and preoperative period. By mapping the sequence of breast events in our study population, we found that MRI is usually among the last breast events before primary surgical treatment, so relatively few biopsies are likely to occur because of MRI among older women. Furthermore, when we examined the subgroup of women with an imaging event postdiagnosis, we found a significantly smaller percent of the women had biopsies following an MRI, compared with women whose biopsy followed a mammogram and US. These findings are important when evaluating the potential risks and benefits of preoperative MRI. If relatively few additional biopsies result from MRI, then that may be a less likely potential harm, yet may afford the benefit of better determining extent of disease before the primary surgery. Similar to other studies reporting longer periods between imaging and treatment 13, 18 we found the MRI group to be delayed by a week compared with the other groups. Although these delays are not likely to affect recurrence or mortality, women need this evidence to help them weigh any potential benefit against risks that may be important to them, such as anxiety due to longer time between initial imaging and their definitive treatment.
Our examination of entire care episodes associated with breast cancer diagnosis and initial surgical management in a large nationally representative sample is unique, but we note limitations, including age restriction to 66+, generalizability to fee-for-service delivery systems only, inability to account for women's preferences, or clinical rationale, such as monitoring neoadjuvant chemotherapy. Also, breast density is not available in SEER-Medicare data, therefore we were not able adjust for breast density in the model. Although we examined MRI use by year, there may be heterogeneity of patterns of care within episodes. These limitations were considered when interpreting our results.
Because studies in both older and younger women with breast cancer have shown an increased use of breast MRI during the preoperative period-with between 22% and 68% receiving MRI, 28, 29 generating evidence to weigh the factors likely to be involved in the tradeoffs of benefit and limitations, is important.
Our study demonstrates that older women receiving diagnostic/preoperative MRI undergo more breast events than those without MRI and is most often performed as the final test. Our finding of 4000 different breast event combinations indicates there is much variability in the diagnostic/ preoperative work-up in older women, demonstrating the opportunity to increase standardization as a means to optimize clinical care. 
